Theravance Biopharma Strategy and Business Model

Executive Overview

Theravance Biopharma is a small-cap biopharmaceutical company focused on specialty medicines for serious diseases where a focused clinical and commercial model can matter more than scale. Formed as an independent company in 2014 and headquartered in South San Francisco, California, Theravance Biopharma today is economically concentrated in one marketed product, YUPELRI, a once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD), commercialized in the United States through a collaboration with Viatris. Its principal pipeline asset as of 2024 public disclosures is ampreloxetine, a norepinephrine reuptake inhibitor being developed for symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy after mixed results in a broader autonomic-failure population in 2023.

That makes Theravance Biopharma a hybrid business: part commercial-stage specialty pharma, part development-stage biotech. In FY2023, the company reported approximately $59 million of revenue, largely tied to collaboration economics from YUPELRI. Strategically, the company is not trying to be a broad, fully integrated global pharma player. Its model is narrower and more capital-conscious: use partnerships where they make sense, keep the fixed-cost base relatively lean, and concentrate resources on a small number of differentiated assets where clinical evidence, regulatory execution, and targeted commercialization can create value.

Theravance Biopharma at a Glance

Logo
Common name	Theravance Biopharma
Full legal name	Theravance Biopharma, Inc.
Headquarters	South San Francisco, California, United States
Ownership	Public company
Ticker	TBPH
Exchange	NASDAQ
Market Cap	$877.95M
Revenue (FY2024)	#N/A
Founding / major historical milestones	2014 spin-off from Theravance, Inc.; 2018 U.S. approval of YUPELRI; 2023 ampreloxetine Phase 3 setback led to a narrower development focus on multiple system atrophy-related symptomatic neurogenic orthostatic hypotension
Industry or industries	Biotechnology; specialty pharmaceuticals
Key products or services	YUPELRI (revefenacin) for COPD; ampreloxetine (investigational); drug development, licensing, and collaboration activities
Geographic footprint	Headquartered in the United States; commercial exposure centered on the U.S. market; development activities can involve multi-country clinical sites and outsourced global manufacturing
Business segments as officially reported	One operating and reportable segment
Company website	https://www.theravance.com

1. What Is the Strategy of Theravance Biopharma?

Theravance Biopharma’s public disclosures through 2024 point to a focused, capital-conscious specialty biopharma strategy rather than a broad portfolio strategy. Using the Playing to Win framework, the company’s approach can be summarized as follows.

1. 1a. What is the winning aspiration of Theravance Biopharma?

   Theravance Biopharma’s winning aspiration appears to be to create shareholder value by developing and commercializing differentiated medicines for serious diseases where a smaller company can compete effectively through focus. As of 2024, that translates into two practical goals: maximize the commercial value of YUPELRI in the U.S. COPD market and advance ampreloxetine in a more targeted indication after the broader 2023 Phase 3 setback. The company has not publicly framed success as becoming a large, diversified pharma company, and it has not emphasized broad top-line scale targets. Instead, “winning” appears to mean pairing one repeat-prescription commercial asset with carefully selected pipeline bets and disciplined spending.

2. 1b. Where does Theravance Biopharma play?

   Theravance Biopharma plays in specialist-managed therapeutic areas where differentiated clinical positioning can matter and where commercialization does not necessarily require a massive primary-care infrastructure. In practice, its current competitive field is concentrated in respiratory medicine, especially COPD patients for whom nebulized maintenance therapy is clinically relevant, and in neurology/autonomic disorders through ampreloxetine’s development path in multiple system atrophy-related symptomatic neurogenic orthostatic hypotension. Geographically, the business is centered on the United States commercially, with development activities that can span multiple countries through outsourced trial and manufacturing networks.

3. 1c. How does Theravance Biopharma plan to win?

   Theravance Biopharma plans to win through specialization rather than breadth. For YUPELRI, the value proposition is a once-daily nebulized maintenance therapy for COPD, a niche that matters for patients who cannot reliably use handheld inhalers or who are better served by nebulized delivery. For pipeline development, the company’s public posture after 2023 suggests a narrower, more biologically and clinically targeted approach rather than pursuing the broadest possible label. Just as important, Theravance Biopharma uses partnerships to reduce fixed commercial costs. The Viatris collaboration lets the company participate in commercial economics without carrying the full burden of a large standalone sales and distribution infrastructure.

4. 1d. What capabilities must Theravance Biopharma have in place?

   To execute this strategy, Theravance Biopharma needs strong capabilities in late-stage clinical development, regulatory interaction, medical affairs, alliance management, and outsourced manufacturing oversight. Because the company is relatively small, it also needs to be unusually good at portfolio prioritization. In a concentrated model, one clinical readout, one reimbursement change, or one supply disruption can matter disproportionately. Its capabilities therefore need to be less about running a vast global organization and more about making a few high-stakes decisions well.

5. 1e. What management systems does Theravance Biopharma require?

   Theravance Biopharma requires management systems built around milestone-based R&D governance, careful cash planning, quality and pharmacovigilance compliance, and structured partner oversight. The company’s public actions after the 2023 ampreloxetine disappointment suggest a willingness to review programs critically and narrow focus when data do not support broader ambitions. For a company of this size, strategy execution depends on disciplined portfolio reviews, clinical-go/no-go criteria, operating-expense control, and clear governance of collaboration agreements, especially around YUPELRI commercialization and supply.

2. What Are the Current Strategic Initiatives of Theravance Biopharma?

As of 2024 public communications, Theravance Biopharma’s strategic agenda is fairly concentrated. The company is not juggling a broad set of late-stage launches. It is focused on a small number of initiatives that matter materially to valuation and cash flow.

• Drive YUPELRI prescription growth in the U.S. COPD market. Theravance Biopharma continues to emphasize commercial execution around YUPELRI with Viatris. The logic is straightforward: YUPELRI is the company’s main repeat-driven revenue source, and its growth depends on penetration among patients who need or benefit from nebulized maintenance therapy, including patients with severe disease, inhaler technique limitations, and care transitions from hospital to home or long-term care settings.
• Advance ampreloxetine through a narrower development path. After the broader Phase 3 study in symptomatic neurogenic orthostatic hypotension did not meet its primary endpoint in 2023, management’s public stance shifted toward patients with multiple system atrophy, where the company believes the biology and clinical signal may be more favorable. The strategic initiative is therefore not generic pipeline expansion; it is targeted regulatory and clinical work to determine whether a focused path can support approval in a narrower population.
• Preserve financial flexibility through portfolio discipline. Theravance Biopharma’s public messaging indicates a continued focus on capital allocation and expense control. For a company with limited revenue concentration and binary development risk, conserving cash and prioritizing the highest-probability assets are themselves strategic initiatives, not just finance housekeeping.
• Use partnerships to extend reach without building a full-scale commercial machine. The Viatris relationship remains central to how Theravance Biopharma commercializes YUPELRI. More broadly, the company’s model suggests that external partnerships and outsourced execution are preferred where they can lower fixed costs, reduce infrastructure burden, or add market access capabilities that the company would find expensive to build alone.

3. What Is the Business Model of Theravance Biopharma?

Theravance Biopharma operates a hybrid business model that combines recurring economics from a commercial respiratory product with the risk-reward profile of a development-stage biotech pipeline.

• What customers actually buy: End customers buy prescription medicines. Today, the main marketed therapy tied to Theravance Biopharma’s economics is YUPELRI for COPD maintenance treatment. Immediate contractual counterparties are more complex than in a simple pharma model because the company commercializes through a collaboration rather than selling everything entirely on its own.
• Recurring versus one-time revenue: YUPELRI is used in chronic disease management, so its commercial economics are repeat-driven. By contrast, license fees, milestones, or other collaboration payments are episodic and less predictable. That mix matters because recurring product demand helps support operating continuity, while milestone-style revenue does not.
• How pricing power works: Pricing power in specialty pharma comes from clinical differentiation, intellectual property, regulatory exclusivity, and payer access. In Theravance Biopharma’s case, realized pricing is still constrained by formularies, rebates, Medicare dynamics, and the fact that COPD has many alternative maintenance therapies. So the company has some branded-drug pricing leverage, but not unconstrained pricing power.
• Why the business mix matters: Theravance Biopharma’s economics are concentrated. A single commercial product supplies most repeat-driven revenue, while pipeline assets create optionality but also binary risk. This mix can be attractive if the marketed asset keeps growing and the pipeline converts, but it also means execution risk is high because there are fewer offsets when something underperforms.
• What drives margins and cash generation: The company’s physical manufacturing base is relatively light because it relies heavily on outsourcing and partnerships. Capital expenditure needs are therefore modest compared with industrial or large-scale manufacturing businesses. Cash generation is driven less by plant utilization and more by product demand, collaboration economics, R&D spend, and the timing of clinical programs. Reported gross margin is less informative than in a fully integrated pharma company because collaboration accounting can dominate the income statement; operating margin is mainly shaped by R&D intensity and the fixed cost of being a public biotech.
• Revenue model: This is a prescription-drug and collaboration model, not a subscription or pay-per-use model. The main recurring element is repeat prescription demand for YUPELRI. Future upside would come from additional approved products, lifecycle management, and partnership-related revenue streams.

4. What Products and/or Services Does Theravance Biopharma Sell?

The most important current offering is clearly YUPELRI. It is strategically important not just because it is approved, but because it anchors Theravance Biopharma’s business model in a real commercial market instead of making the company entirely dependent on financing and binary trial outcomes.

Ampreloxetine is the most important noncommercial asset. It has outsized strategic significance because a positive regulatory and clinical path in multiple system atrophy could diversify the business beyond respiratory medicine and create a second value driver. By contrast, legacy assets and older programs are much less central to the current story. Theravance Biopharma historically had a broader portfolio, but by 2024 the company’s strategic identity was much more concentrated around YUPELRI and ampreloxetine.

5. What Are the Key Competitors or Peers of Theravance Biopharma?

Theravance Biopharma does not compete as a broad-headquartered pharmaceutical giant. Its competitive set is better understood by product area: respiratory maintenance therapy for COPD and, if ampreloxetine advances, treatments used for symptomatic neurogenic orthostatic hypotension.

6. What Is the Marketing Strategy of Theravance Biopharma?

Theravance Biopharma’s marketing strategy is shaped by two facts: it has a narrow product portfolio, and its main marketed asset is commercialized through a partner. As a result, marketing appears to be a supporting capability rather than the company’s defining strategic moat.

For YUPELRI, the practical marketing approach is specialist-focused and evidence-driven. The relevant audiences are pulmonologists, high-prescribing COPD clinicians, health systems, long-term care channels, and payers. The product’s positioning is based less on mass consumer branding and more on clinical fit: once-daily nebulized maintenance therapy for patients for whom nebulized delivery is appropriate. In that kind of market, formulary access, reimbursement support, medical education, and targeted field promotion typically matter more than broad direct-to-consumer advertising.

For pipeline assets such as ampreloxetine, prelaunch “marketing” is mostly scientific rather than commercial. Conference presentations, regulatory positioning, medical affairs engagement, and disease-state education matter more than classic brand campaigns. That is typical for small biopharma companies operating in specialist and rare-disease-adjacent markets.

7. What Are the Key Customer Segments of Theravance Biopharma?

Theravance Biopharma’s customer base should be understood at two levels: immediate commercial counterparties and end-market users.

• Collaboration counterparties: The company’s most important immediate commercial relationship is with Viatris for YUPELRI. That matters because Theravance Biopharma’s realized economics depend on a partner’s commercial execution, not only on end-user demand.
• COPD patients appropriate for nebulized maintenance therapy: This is the core end market for YUPELRI. It includes patients who may struggle with handheld inhalers, have advanced disease, or are treated in settings where nebulized administration is preferred.
• Prescribers: Pulmonologists are central, but primary care physicians, hospital-based clinicians, and post-acute care prescribers also matter in COPD treatment pathways.
• Payers and pharmacy-benefit decision-makers: Medicare-related reimbursement, managed-care coverage, and formulary positioning are critical because COPD treatment adherence and product uptake are highly sensitive to access.
• Institutional and channel customers: Long-term care pharmacies, hospitals, home-care providers, and distribution intermediaries are important because nebulized therapies often sit inside more complex care pathways than simple retail prescriptions.
• Future neurology customers: If ampreloxetine progresses, the key customer set would likely include neurologists, autonomic specialists, centers treating multiple system atrophy, and the payers covering rare or specialist-managed diseases.

Overall, Theravance Biopharma is not broadly diversified by end market today. Its economic exposure is still heavily concentrated in the U.S. COPD market.

8. What Is the Sales Model of Theravance Biopharma?

Theravance Biopharma’s sales model is partnership-led rather than fully direct. The company participates in the economics of YUPELRI through its collaboration with Viatris, which handles commercialization. That means Theravance Biopharma benefits from product growth without building the same scale of sales force, contracting infrastructure, and channel-management overhead that a standalone respiratory company would need.

This structure has trade-offs. On the positive side, it lowers fixed costs, reduces execution complexity, and fits the company’s size. On the negative side, it gives Theravance Biopharma less direct control over field-force intensity, channel priorities, and day-to-day commercial tactics than a fully integrated company would have.

If ampreloxetine reaches market, Theravance Biopharma would likely face a strategic choice: build a small targeted specialty sales model or partner the asset. Because the likely prescriber base would be concentrated among neurologists and autonomic specialists, the product would not necessarily require a massive national primary-care sales force. That creates a credible path to a focused specialty-commercial model if management ever chooses to commercialize more directly.

9. In What Geographies Does Theravance Biopharma Operate?

Theravance Biopharma’s operational footprint is more concentrated than that of large multinational pharmaceutical companies. Its headquarters are in South San Francisco, California, and its principal commercial exposure as of 2024 is the United States through YUPELRI.

That does not mean the company is purely domestic in every operational sense. Clinical development programs can involve international trial sites, and outsourced manufacturing and supply-chain activities may span multiple countries, as is common in biopharma. But from a revenue and go-to-market standpoint, Theravance Biopharma is not broadly diversified across dozens of commercial geographies. The company’s business is still predominantly tied to the U.S. market.

This geographic concentration matters strategically. It simplifies commercialization and compliance relative to a global rollout, but it also increases dependence on U.S. reimbursement dynamics, U.S. prescribing trends, and the execution of a single primary market.

10. Who Are the Owners of Theravance Biopharma?

Theravance Biopharma is a publicly traded company listed under the ticker TBPH. As of the company’s 2024 proxy-era disclosures, it did not appear to have a controlling shareholder with majority voting power. Ownership was therefore better characterized as institutionally held and dispersed rather than founder-controlled, family-controlled, or government-controlled. Because small-cap biotech ownership can shift meaningfully as specialist healthcare funds build or reduce positions, the latest proxy statement and recent Schedule 13D or 13G filings are the best sources for the most current large-holder picture.

11. How Is Theravance Biopharma Organized?

Theravance Biopharma reports as a single operating and reportable segment, which is typical for a company of its size and portfolio concentration. That does not mean the business is organizationally simple in practice, but it does mean the company does not publicly present itself as a multi-division portfolio company with separate segments by franchise or geography.

• Commercial economics: YUPELRI is managed through a collaboration structure rather than a fully standalone commercial division.
• Core internal functions: Clinical development, regulatory affairs, medical affairs, quality, finance, legal, and corporate administration remain central.
• External execution layer: Contract research organizations, contract development and manufacturing organizations, and commercial partners perform work that larger pharma companies may do internally.

Practically, this is a lean biopharma operating model organized around asset management and external coordination as much as around internal execution.

12. How Does Theravance Biopharma Operate?

On a day-to-day basis, Theravance Biopharma operates like a focused asset manager in biopharma rather than like a large integrated manufacturer. The company creates value by selecting drug candidates, generating clinical evidence, working with regulators, managing intellectual property, overseeing safety and quality, and coordinating a network of external partners.

• Commercial operations: Monitor YUPELRI demand trends, work through alliance governance with Viatris, support medical and market-access needs, and manage revenue-sharing or collaboration economics.
• Development operations: Design and execute clinical studies, recruit sites and patients, monitor data quality, analyze trial results, and interact with regulators.
• Manufacturing oversight: Manage external suppliers and manufacturing partners, ensure current Good Manufacturing Practice compliance, and coordinate product supply and release.
• Medical and safety operations: Handle pharmacovigilance, post-marketing surveillance, and medical-information responsibilities.
• Corporate operations: Manage cash runway, investor communications, legal obligations, and public-company governance.

Its main operational complexities are the ones common to concentrated biotech businesses: dependence on a small number of assets, reliance on partners and contractors, regulatory uncertainty, and the need to balance clinical ambition against limited resources.

13. What Are the Growth Opportunities for Theravance Biopharma?

• Deeper YUPELRI penetration in appropriate COPD patients: The clearest near-term growth opportunity is continued uptake in the U.S. among patients who need nebulized maintenance therapy. That can come from stronger physician awareness, better channel execution, and improved pull-through in long-term care, hospital discharge, and home-nebulization pathways.
• Ampreloxetine in multiple system atrophy-related symptomatic neurogenic orthostatic hypotension: If the company can define a viable regulatory path and generate convincing data in the narrower target population, ampreloxetine could become a meaningful second value driver.
• Lifecycle and evidence expansion around YUPELRI: Even without major new label expansions, better real-world evidence, guideline visibility, or stronger positioning in specific care settings could support incremental growth.
• Selective business development: While not the centerpiece of the 2024 equity story, Theravance Biopharma’s lean infrastructure could support targeted in-licensing or partnerships in specialist areas if management identifies assets that fit its economic and operational model. This is more a reasonable external synthesis than a clearly stated near-term priority.

The main constraints are equally clear: product concentration, intense competition in COPD maintenance therapy, payer pressure, clinical and regulatory risk around ampreloxetine, and dependence on partners for commercialization and supply-chain execution.

14. What Is the History of Theravance Biopharma?

Theravance Biopharma was created in 2014 through the separation of the biopharmaceutical business of Theravance, Inc., which later became Innoviva. That spin-off established Theravance Biopharma as an independent public company with a portfolio spanning respiratory, inflammation, and other specialty therapeutic programs.

Over time, the company’s portfolio became more focused. One major milestone was the U.S. approval of YUPELRI in 2018 for maintenance treatment of COPD, giving the company a marketed respiratory asset and a commercial revenue stream. Theravance Biopharma also historically reshaped its portfolio through partnering and the exit of noncore assets, reflecting the reality that small biopharma companies rarely commercialize every program internally.

A more recent turning point came in 2023, when the Phase 3 readout for ampreloxetine in a broader symptomatic neurogenic orthostatic hypotension population did not meet the primary endpoint. Rather than continue unchanged, management shifted toward a narrower development focus on multiple system atrophy-associated disease. That episode captures an important feature of the company’s history: strategy has repeatedly been shaped by clinical data, not by portfolio breadth for its own sake.

15. What Are the Key Suppliers to Theravance Biopharma?

Suppliers matter meaningfully to Theravance Biopharma because it operates with an outsourced biopharma model. Public filings do not generally foreground a long named list of suppliers, which is common in the industry, but the critical supplier categories are clear.

• Active pharmaceutical ingredient suppliers: These vendors provide the drug substance used in commercial and clinical products.
• Drug-product manufacturing and fill-finish partners: Especially important for inhalation solutions and clinical-trial material.
• Packaging suppliers: For unit-dose presentation, labeling, and compliance with pharmaceutical handling requirements.
• Contract research organizations: Essential for clinical operations, site monitoring, data management, and biostatistics.
• Laboratory and testing vendors: Needed for stability testing, release testing, and quality control.
• Logistics providers: Important for product handling, warehousing, and clinical-supply distribution.

Supplier structure matters strategically because a small company with a narrow portfolio can be more exposed to single-source or limited-source risk than a diversified pharma company. In Theravance Biopharma’s case, manufacturing reliability, quality compliance, and continuity of supply are especially important because one marketed product drives most recurring economics.

16. What Are the Key Brands Owned by Theravance Biopharma?

Theravance Biopharma has a narrow brand portfolio. Branding exists, but it is not the main strategic lever in the same way it might be for a consumer health or large primary-care pharma business.

• YUPELRI: The company’s key commercial brand. It is positioned as a once-daily nebulized maintenance treatment for COPD and is most relevant in patient segments where nebulized administration offers practical or clinical advantages.
• Ampreloxetine: An investigational asset rather than a commercial brand. Its strategic importance is high, but brand equity is not yet a factor because it remains in development.

For Theravance Biopharma, clinical evidence, reimbursement, specialist prescribing behavior, and channel execution matter more than broad consumer brand-building. The company’s brand architecture is therefore narrow and medically oriented rather than brand-led in a classic mass-market sense.

17. How Does the Supply Chain of Theravance Biopharma Function?

Theravance Biopharma’s supply chain is typical of a small outsourced pharmaceutical company: it coordinates rather than owns most of the physical production network. That makes supply-chain management a strategic control function rather than a factory-operations function.

• Sourcing: Obtain active ingredients, excipients, packaging materials, and other inputs through qualified suppliers.
• Manufacturing: Use external contract manufacturers for drug substance and drug product, including sterile or otherwise tightly controlled processes where needed.
• Quality release: Conduct required testing, documentation, and batch-release activities to meet regulatory standards.
• Distribution: Move commercial product through the relevant pharmaceutical channels connected to the commercialization partner and downstream providers.
• Clinical supply: For pipeline programs, manufacture and package investigational material in small, controlled batches and route it to trial sites.

For YUPELRI specifically, supply-chain reliability matters because COPD patients use maintenance therapy repeatedly, and prescribing momentum can be damaged by supply interruptions. For development programs, the main supply-chain challenge is often not scale but precision: small-batch consistency, trial logistics, documentation, and regulatory compliance.

18. What Is the R&D Strategy of Theravance Biopharma?

R&D is central to Theravance Biopharma’s identity, but its R&D strategy as of 2024 is more selective than expansive. The company’s public posture suggests that it is prioritizing fewer assets with clearer potential differentiation rather than trying to sustain a broad discovery engine across many unrelated programs.

Historically, Theravance Biopharma developed expertise in respiratory pharmacology and other specialty therapeutic areas. YUPELRI reflects that heritage by addressing a defined treatment need in COPD with a delivery format that differs from standard handheld inhalers. As of 2024, the lead internal R&D priority appears to be ampreloxetine, with the key question being whether a narrower indication in multiple system atrophy can produce a registrable path after the broader Phase 3 setback.

The strategic implication is important: Theravance Biopharma’s R&D model appears designed around probability-adjusted capital efficiency. In other words, the company cannot afford a “spray and pray” pipeline. It needs development programs where mechanism, target population, and commercial model are tight enough to justify the spend.

19. What Is the Finance Strategy of Theravance Biopharma?

Theravance Biopharma’s finance strategy appears to center on preserving liquidity, keeping the fixed-cost base manageable, and allocating capital to the highest-probability opportunities. That is typical of small biopharma companies, but it is especially important here because the company has modest recurring revenue relative to large pharma peers and meaningful clinical-development risk.

Several elements stand out. First, the partner-led commercialization model for YUPELRI limits the need for a large SG&A buildout. Second, the outsourced operating model keeps capital expenditure relatively low. Third, the company’s post-2023 portfolio posture suggests that management is willing to narrow development focus when the data do not support broad investment. Taken together, those choices indicate a finance strategy aligned with survival, flexibility, and selective value creation rather than aggressive balance-sheet expansion.

Theravance Biopharma does not fit the profile of a mature dividend-paying pharmaceutical company. Its capital allocation priorities are more likely to involve R&D funding, operational runway, and selective business development than recurring capital returns. For investors and operators alike, the key financial question is how efficiently the company can convert limited commercial cash flow and cash on hand into one or more durable product franchises.

20. How Companies Like Theravance Biopharma Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants who are based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Theravance Biopharma engage Umbrex when they need talent with the training these top global firms provide, but they do not need a full team with all the overhead. Umbrex has consultants across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a focused biopharma company like Theravance Biopharma, the best uses are usually highly targeted, high-stakes projects tied to commercialization, portfolio choices, operating model design, and external-partner execution.

• YUPELRI growth diagnostic: Analyze prescribing data, channel leakage, and patient journey friction points to identify where nebulized COPD adoption can accelerate.
• COPD segmentation and targeting refresh: Rebuild the market map for pulmonologists, long-term care, hospital discharge pathways, and home-nebulization channels.
• Payer and access strategy review: Assess reimbursement barriers, gross-to-net pressure points, and formulary opportunities for a specialist respiratory product.
• Alliance-management PMO: Create stronger governance, KPI dashboards, and joint decision processes for working with a commercialization partner such as Viatris.
• Ampreloxetine indication-prioritization project: Support evidence review, competitive benchmarking, patient-subgroup sizing, and scenario planning for a focused multiple system atrophy launch path.
• Rare-disease launch readiness planning: Design the commercial blueprint, field-force sizing logic, center-of-excellence strategy, and patient-support model that would be required if ampreloxetine advances.
• Portfolio prioritization and capital allocation model: Build a decision framework that ranks internal programs, lifecycle investments, and business-development options by risk-adjusted return.
• Outsourced CMC and supply-chain resilience assessment: Evaluate single-source risk, quality-system handoffs, inventory strategy, and contingency planning across external manufacturers.
• Medical affairs and evidence-generation strategy: Identify the real-world evidence, health-economic evidence, and specialist-education priorities most likely to support uptake.
• Operating model redesign for a lean biopharma: Clarify which functions should remain internal versus outsourced as the company balances one marketed asset with a concentrated pipeline.